PolyPid (PYPD) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $14
Moomoo News07:31 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $14 Price Target
Benzinga07:17 ET
PolyPid Analyst Ratings
Benzinga07:16 ET · Ratings
PolyPid's Strategic Advancements and Clinical Progress: A Buy Recommendation
TipRanks06:36 ET · Ratings
PolyPid Ltd. Announces Research Collaboration With ImmunoGenesis to Enhance Immunotherapy for Solid Tumors
Quiver QuantitativeDec 11 07:15 ET
Express News | PolyPid Announces Research and Development Collaboration With Immunogenesis Leveraging Plex Technology to Enhance Cancer Immunotherapy
ReutersDec 11 07:00 ET

Comments

Jaguar8

11 hours ago

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

16

7

4

Jaguar8

Dec 11 06:06

NEWS

$PolyPid (PYPD.US)$
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Wednesday, 11th December at 7:00 am
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. ("ImmunoGenesis"), a Houston-based cli...

Trytosaveabit

Dec 11 06:01

Update

$PolyPid (PYPD.US)$ Reuters· just
PolyPid Announces Research and Development Collaboration With Immunogenesis Leveraging Plex Technology to Enhance Cancer Immunotherapy

Trytosaveabit

Jun 18 06:21

Make a note!

$PolyPid (PYPD.US)$ Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II
Unblinded Interim Analysis to be Conducted Once Approximately 400 PatientsComplete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025

Jaguar8

Apr 30 06:02

$PolyPid (PYPD.US)$
NEWS
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PYPD PolyPid

Trade Overview

Capital Trend

News

Comments